RT Generic
T1 Up-to-date on the evidence linking miRNA-related epitranscriptomic modifications and disease settings. Can these modifications affect cross-kingdom regulation?
A1 Tome-Carneiro, Joao
A1 Lopez de las Hazas, Maria-Carmen
A1 Boughanem, Hatim
A1 Bottcher, Yvonne
A1 Cayir, Akin
A1 Macias Gonzalez, Manuel
A1 Davalos, Alberto
K1 Epitranscriptomics
K1 miRNA modifications
K1 methylation
K1 m(6)A
K1 cross-kingdom
K1 M(6)a rna methylation
K1 Let-7 microrna expression
K1 Messenger-rna
K1 Plant micrornas
K1 Gene-expression
K1 Yth domain
K1 N-6-methyladenosine rna
K1 Structural basis
K1 Breast-cancer
K1 Promotes
AB The field of epitranscriptomics is rapidly developing. Several modifications (e.g. methylations) have been identified for different RNA types. Current evidence shows that chemical RNA modifications can influence the whole molecule's secondary structure, translatability, functionality, stability, and degradation, and some are dynamically and reversibly modulated. miRNAs, in particular, are not only post-transcriptional modulators of gene expression but are themselves submitted to regulatory mechanisms. Understanding how these modifications are regulated and the resulting pathological consequences when dysregulation occurs is essential for the development of new therapeutic targets. In humans and other mammals, dietary components have been shown to affect miRNA expression and may also induce chemical modifications in miRNAs. The identification of chemical modifications in miRNAs (endogenous and exogenous) that can impact host gene expression opens up an alternative way to select new specific therapeutic targets. Hence, the aim of this review is to briefly address how RNA epitranscriptomic modifications can affect miRNA biogenesis and to summarize the existing evidence showing the connection between the (de)regulation of these processes and disease settings. In addition, we hypothesize on the potential effect certain chemical modifications could have on the potential cross-kingdom journey of dietary plant miRNAs.
PB Taylor & francis inc
SN 1547-6286
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/26955
UL https://hdl.handle.net/10668/26955
LA en
DS RISalud
RD Apr 11, 2025